0000950170-24-025943.txt : 20240305
0000950170-24-025943.hdr.sgml : 20240305
20240305161642
ACCESSION NUMBER: 0000950170-24-025943
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240303
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hughes Eric A
CENTRAL INDEX KEY: 0001938678
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 24720635
MAIL ADDRESS:
STREET 1: C/O TEVA
STREET 2: 5 BASEL STREET, P.O. BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
BUSINESS PHONE: 972 (3) 914-8213
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
4
1
ownership.xml
4
X0508
4
2024-03-03
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001938678
Hughes Eric A
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
false
true
false
false
See "Remarks"
true
Ordinary Shares
2024-03-03
4
M
false
24900
A
24900
D
Ordinary Shares
2024-03-04
4
S
false
8045
13.3373
D
16855
D
Restricted Share Units
2024-03-03
4
M
false
24900
0
D
Ordinary Shares
24900
74701
D
Restricted Share Units
2024-03-04
4
A
false
93005
0
A
Ordinary Shares
93005
93005
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.
Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.
Executive Vice President, Global R&D and Chief Medical Officer
/s/ Dov Bergwerk as attorney-in-fact for Eric Hughes
2024-03-05